GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sangui Biotech International Inc (HAM:SBH) » Definitions » Cyclically Adjusted PS Ratio

Sangui Biotech International (HAM:SBH) Cyclically Adjusted PS Ratio : (As of May. 23, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Sangui Biotech International Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sangui Biotech International Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sangui Biotech International's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sangui Biotech International Cyclically Adjusted PS Ratio Chart

Sangui Biotech International Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Sangui Biotech International Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sangui Biotech International's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sangui Biotech International's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sangui Biotech International's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sangui Biotech International's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sangui Biotech International's Cyclically Adjusted PS Ratio falls into.



Sangui Biotech International Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sangui Biotech International's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2023 is calculated as:

For example, Sangui Biotech International's adjusted Revenue per Share data for the three months ended in Mar. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2023 (Change)*Current CPI (Mar. 2023)
=0/122.4024*122.4024
=0.000

Current CPI (Mar. 2023) = 122.4024.

Sangui Biotech International Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201306 0.000 98.516 0.000
201309 0.000 98.983 0.000
201312 0.000 99.356 0.000
201403 0.000 99.543 0.000
201406 0.000 99.543 0.000
201409 0.000 99.823 0.000
201412 0.000 99.543 0.000
201503 0.000 99.717 0.000
201506 0.000 100.417 0.000
201509 0.000 100.417 0.000
201512 0.000 99.717 0.000
201603 0.000 100.017 0.000
201606 0.000 100.717 0.000
201609 0.000 101.017 0.000
201612 0.000 101.217 0.000
201703 0.000 101.417 0.000
201706 0.000 102.117 0.000
201709 0.000 102.717 0.000
201712 0.000 102.617 0.000
201803 0.000 102.917 0.000
201806 0.000 104.017 0.000
201809 0.000 104.718 0.000
201812 0.000 104.217 0.000
201903 0.000 104.217 0.000
201906 0.000 105.718 0.000
201909 0.000 106.018 0.000
201912 0.000 105.818 0.000
202003 0.000 105.718 0.000
202006 0.000 106.618 0.000
202009 0.000 105.818 0.000
202012 0.000 105.518 0.000
202103 0.000 107.518 0.000
202106 0.000 108.486 0.000
202109 0.000 109.435 0.000
202112 0.000 110.384 0.000
202203 0.000 113.968 0.000
202206 0.000 115.760 0.000
202209 0.000 118.818 0.000
202212 0.000 119.345 0.000
202303 0.000 122.402 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sangui Biotech International  (HAM:SBH) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sangui Biotech International Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sangui Biotech International's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sangui Biotech International (HAM:SBH) Business Description

Traded in Other Exchanges
Address
Bleichenbrucke 9, Hamburg, DEU, 20354
Sangui Biotech International Inc develops pharmaceutical, medical and cosmetic products, through its subsidiary. The company develops oxygen carriers for providing oxygen transport in humans due to acute or chronic lack of oxygen and in the case of chronic wounds. It has also developed external applications of oxygen transporters in the form of sprays for healing chronic wounds and gels and emulsions for the regeneration of the skin. The products offered are artificial oxygen carriers; Chitoskin wound pads; and haemoglobin-based wound spray technology sold under the brand name Granulox. It derives revenue from licensing fees on sales of its wound spray product.